Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV
JACC: Heart Failure · 2026-08 · 103284
DOI: 10.1016/j.jchf.2026.103284 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Heart Failure, 2026-08. Verfasst von Kosei Terada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford…. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NHLBI.
Abstract (Originalsprache)
Tweet: In heart transplant recipients, alirocumab attenuated cardiac allograft vasculopathy progression only in patients with concomitantly elevated LDL-C and lipoprotein(a). Lipid phenotype–guided risk stratification may identify those most likely to benefit from PCSK9 inhibition after heart transplantation. #PCSK9inhibition #CAV #HeartTransplantation
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA.
- Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA; Stanford Diabetes Research Center, Stanford Prevent…
- Kaiser Permanente, Santa Clara, California, USA.
- Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA; VA Palo Alto Health Care System, Palo Alto, Califor…
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NHLBI
Zitieren
APA
Terada, K., Takahashi, K., Khush, K. K., Nishi, T., Knowles, J. W., Skoda, A., Varr, B., Woo, C., Honda, Y., & Fearon, W. F. (2026). Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV. JACC: Heart Failure, 103284. https://doi.org/10.1016/j.jchf.2026.103284
Vancouver
Terada K, Takahashi K, Khush KK, Nishi T, Knowles JW, Skoda A, et al. Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV. JACC: Heart Failure. 2026:103284. doi:10.1016/j.jchf.2026.103284
BibTeX
@article{Terada2026,
author = {Terada, Kosei and Takahashi, Kuniaki and Khush, Kiran K and Nishi, Takeshi and Knowles, Joshua W and Skoda, Anette and Varr, Brandon and Woo, Christopher and Honda, Yasuhiro and Fearon, William F},
title = {Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV},
journal = {JACC: Heart Failure},
year = {2026},
pages = {103284},
doi = {10.1016/j.jchf.2026.103284}
}
EUVIMED